2017年6月5日——学术报告

发布时间:2017-06-01浏览次数:29

  

报告题目(Title)Cyclic nucleotide phosphodiesterase-4 (PDE4) subtypes as potential targets for neuropsychiatric drugs.

报告人(Speaker)Dr. James M. O'Donnell, Professor and Dean of the School of Pharmacy and Pharmaceutical Sciences at the State University of New York (SUNY) at Buffalo, NY,                                 USA.

时间 (Time)201765上午09:30

地点 (Place):敏行楼316(护理系教室)

  

报告内容简介 (Brief Abstract):

Considerable preclinical and clinical evidence suggests that inhibitors of PDE4 have effects on central nervous system function and behavior consistent with therapeutic utility for treating disorders such as depression and dementia. Despite this promise, dose-limiting side effects such as nausea and emesis has slowed drug development. Limiting drug action to specific PDE4 subtypes (i.e., PDE4A, B, C, and D) offers a means to produce therapeutic effects while minimizing side effects. However, the highly conserved catalytic site, to which classical PDE4 inhibitors bind, has limited the discovery of subtype-selective inhibitors. Recently, it has been shown that allosteric inhibitors, which do not bind to the catalytic site, can demonstrate subtype selectivity. Our research has shown distinct pharmacological profiles for selective inhibitors of PDE4B and PDE4D in models to assess antidepressant and memory-enhancing efficacy.